News >

Expert Shares Treatment Updates for Neuroendocrine Tumors

Danielle Bucco
Published: Tuesday, Apr 10, 2018

Emily K. Bergsland, MD

Emily K. Bergsland, MD
The incidence of neuroendocrine tumors (NETs) has increased 5-fold over the past 30 years, making it the second most prevalent diagnosis in gastrointestinal (GI) malignancies, explains Emily K. Bergsland, MD, a professor of medicine at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.1

“Resection of the disease continues to be a treatment for patients with well-differentiated gastroenteropancreatic (GEP)- NETs and is still conducted in more than 70% of patients with these tumors. However, the recurrence rate for patients who received a resection is 100% at 10 years, changing the treatment paradigm as this was previously considered a curative therapy,” said Bergsland in her presentation at the 2018 OncLive® State of the Science SummitTM on Gastrointestinal Cancers.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication